Tag Archives: Ionis Pharmaceuticals

Wainzua Receives EU Recommendation for Treating Hereditary Amyloidosis, Offering New Monthly Self-Administered Option

(IN BRIEF) AstraZeneca and Ionis’ drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adults with stage 1 or 2 polyneuropathy. Based on the positive results from the NEURO-TTRansform Phase … Read the full press release

Novartis collaborates with Ionis and Akcea to license two novel treatments to reduce cardiovascular risk in patients with high levels of lipoproteins

Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated levels of lipoprotein Lp(a) or ApoCIII, which is a potent regulator of triglycerides … Read the full press release